OCTOBER 2022LIFE SCIENCES REVIEW6Immunotherapy or the use of the body's immune system to fight cancer, has gained immense traction in the past few years. It ensures long-term cancer protection with fewer side effects across different cancer types, including melanoma, prostate cancer, and breast cancer, to name a few. The success and wide adoption of immunotherapy have contributed to the growth of this market. According to reports, the cancer immunotherapy market is expected to grow at a CAGR of 13.8 percent from 2018 to 2024 to reach $152.83 billion by 2024. Several innovative start-ups are also entering this field, and the research works have witnessed tremendous acceleration.Most of these researches are dedicated to finding ways to boost the immune system. For example, several works are being conducted in the fields of Chimeric antigen receptor (CAR) T-cell therapy and Tumor-infiltrating lymphocytes and interleukin-2 (IL-2). Also, till now, the success of immunotherapy has been restricted to the field of liquid tumors; patients with solid tumors were never able to reap the benefits of this advanced treatment method. Research work in this specific area has also been accelerated. With all these advancements, it won't be an overstatement that the cancer immunotherapy space will gain significant traction in the coming years and several innovative and novel treatment methods will surface. But the efficacy of these processes will be proved only after proper pre-clinical and clinical studies. In this edition, our aim is to make readers acquainted with the recent developments in the cancer immunotherapy field to help them understand the market and research trends.Let us know your thoughts.EDITORIALThe Evolving Cancer Immunotherapy ArenaCopyright © 2022 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com OCTOBER - 03 - 2022, Vol 03, Issue - 21 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasVisualizersRonald DonovanDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsVictor Cruz Clara Matthew
< Page 5 | Page 7 >